CO2021013030A2 - Inhibidores de la proteína tirosina fosfatasa - Google Patents
Inhibidores de la proteína tirosina fosfatasaInfo
- Publication number
- CO2021013030A2 CO2021013030A2 CONC2021/0013030A CO2021013030A CO2021013030A2 CO 2021013030 A2 CO2021013030 A2 CO 2021013030A2 CO 2021013030 A CO2021013030 A CO 2021013030A CO 2021013030 A2 CO2021013030 A2 CO 2021013030A2
- Authority
- CO
- Colombia
- Prior art keywords
- protein tyrosine
- tyrosine phosphatase
- phosphatase inhibitors
- tautomer
- stereoisomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos de la Fórmula I o un estereoisómero, tautómero, profármaco o sal aceptable desde el punto de vista farmacéutico de este, que son útiles para el tratamiento de enfermedades hiperproliferativas. Se divulgan métodos para usar los compuestos de la Fórmula I o un estereoisómero, tautómero, profármaco o sal aceptable desde el punto de vista farmacéutico de estos, para el diagnóstico in vitro, in situ e in vivo, la prevención o el tratamiento de dichos trastornos en células de mamífero, o las afecciones patológicas relacionadas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828356P | 2019-04-02 | 2019-04-02 | |
US202062992558P | 2020-03-20 | 2020-03-20 | |
PCT/IB2020/053019 WO2020201991A1 (en) | 2019-04-02 | 2020-03-30 | Protein tyrosine phosphatase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021013030A2 true CO2021013030A2 (es) | 2021-10-20 |
Family
ID=70277430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0013030A CO2021013030A2 (es) | 2019-04-02 | 2021-09-29 | Inhibidores de la proteína tirosina fosfatasa |
Country Status (24)
Country | Link |
---|---|
US (3) | US11634417B2 (es) |
EP (1) | EP3947367A1 (es) |
JP (2) | JP7284830B2 (es) |
KR (1) | KR20210146389A (es) |
CN (1) | CN113874363A (es) |
AU (1) | AU2020251841A1 (es) |
BR (1) | BR112021018664A2 (es) |
CA (1) | CA3135555C (es) |
CL (1) | CL2021002542A1 (es) |
CO (1) | CO2021013030A2 (es) |
CR (1) | CR20210501A (es) |
CU (1) | CU20210080A7 (es) |
DO (1) | DOP2021000206A (es) |
EC (1) | ECSP21072994A (es) |
GE (1) | GEP20237561B (es) |
IL (1) | IL286462A (es) |
MA (1) | MA55511A (es) |
MX (1) | MX2021012122A (es) |
PE (1) | PE20220141A1 (es) |
SG (1) | SG11202110502PA (es) |
TW (1) | TWI766261B (es) |
UY (1) | UY38628A (es) |
WO (1) | WO2020201991A1 (es) |
ZA (1) | ZA202108443B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶-1,6(2h,7h)-二酮 |
WO2022206684A1 (zh) * | 2021-03-31 | 2022-10-06 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
WO2022208408A1 (en) | 2021-04-01 | 2022-10-06 | Array Biopharma Inc. | Crystalline form of a shp2 inhibitor |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技(上海)有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
CN115960109A (zh) * | 2021-05-31 | 2023-04-14 | 药雅科技(上海)有限公司 | 稠环类shp2磷酸酶抑制剂的制备及其应用 |
KR20230011245A (ko) | 2021-07-09 | 2023-01-20 | 주식회사 카나프테라퓨틱스 | Shp2 억제제 및 이의 용도 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
CN118076592A (zh) * | 2021-10-14 | 2024-05-24 | 北京泰德制药股份有限公司 | Shp2抑制剂、包含其的药物组合物及其用途 |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023180898A1 (en) | 2022-03-23 | 2023-09-28 | Array Biopharma Inc. | Crystalline salt form of a shp2 inhibitor |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US7834178B2 (en) | 2006-03-01 | 2010-11-16 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
KR20200003245A (ko) | 2011-10-14 | 2020-01-08 | 어레이 바이오파마 인크. | 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물 |
CA2882750A1 (en) | 2012-08-27 | 2014-03-06 | Jim Blake | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
CA2923533C (en) | 2013-09-30 | 2019-08-06 | Korea Research Institute Of Chemical Technology | Triazolopyrazine derivatives and uses thereof |
EP3094629B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
US10287266B2 (en) * | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
WO2016203404A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
EP3463343B1 (en) | 2016-05-31 | 2022-03-23 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of ptpn11 |
EP3464272B1 (en) | 2016-06-07 | 2021-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
SG11201900157RA (en) * | 2016-07-12 | 2019-02-27 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
KR102665763B1 (ko) | 2017-01-23 | 2024-05-10 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 이환 화합물 |
AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
CA3074304A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
AU2018347516A1 (en) | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
KR20200099530A (ko) | 2017-12-15 | 2020-08-24 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 다환식 화합물 |
US11426422B2 (en) | 2018-01-30 | 2022-08-30 | Research Development Foundation | SHP2 inhibitors and methods of use thereof |
CN112166110B (zh) | 2018-03-21 | 2023-08-11 | 传达治疗有限公司 | Shp2磷酸酶抑制剂及其使用方法 |
EP3768680A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
CN112368272B (zh) | 2018-03-21 | 2023-04-21 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
BR112021002327A2 (pt) | 2018-08-10 | 2021-05-04 | Navire Pharma, Inc. | derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer |
US20210393623A1 (en) * | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
PL3867238T3 (pl) | 2018-10-17 | 2023-09-11 | Array Biopharma Inc. | Inhibitory białkowej fosfatazy tyrozynowej |
-
2020
- 2020-03-30 JP JP2021558566A patent/JP7284830B2/ja active Active
- 2020-03-30 KR KR1020217035641A patent/KR20210146389A/ko not_active Application Discontinuation
- 2020-03-30 MX MX2021012122A patent/MX2021012122A/es unknown
- 2020-03-30 CN CN202080036271.6A patent/CN113874363A/zh active Pending
- 2020-03-30 CU CU2021000080A patent/CU20210080A7/es unknown
- 2020-03-30 AU AU2020251841A patent/AU2020251841A1/en active Pending
- 2020-03-30 SG SG11202110502PA patent/SG11202110502PA/en unknown
- 2020-03-30 BR BR112021018664A patent/BR112021018664A2/pt unknown
- 2020-03-30 GE GEAP202015746A patent/GEP20237561B/en unknown
- 2020-03-30 MA MA055511A patent/MA55511A/fr unknown
- 2020-03-30 EP EP20718387.2A patent/EP3947367A1/en active Pending
- 2020-03-30 WO PCT/IB2020/053019 patent/WO2020201991A1/en unknown
- 2020-03-30 CR CR20210501A patent/CR20210501A/es unknown
- 2020-03-30 CA CA3135555A patent/CA3135555C/en active Active
- 2020-03-30 PE PE2021001646A patent/PE20220141A1/es unknown
- 2020-03-31 US US16/835,702 patent/US11634417B2/en active Active
- 2020-04-01 UY UY0001038628A patent/UY38628A/es unknown
- 2020-04-01 TW TW109111284A patent/TWI766261B/zh active
-
2021
- 2021-09-19 IL IL286462A patent/IL286462A/en unknown
- 2021-09-29 CO CONC2021/0013030A patent/CO2021013030A2/es unknown
- 2021-09-30 CL CL2021002542A patent/CL2021002542A1/es unknown
- 2021-09-30 DO DO2021000206A patent/DOP2021000206A/es unknown
- 2021-09-30 EC ECSENADI202172994A patent/ECSP21072994A/es unknown
- 2021-10-29 ZA ZA2021/08443A patent/ZA202108443B/en unknown
-
2022
- 2022-04-13 US US17/720,070 patent/US11884664B2/en active Active
-
2023
- 2023-03-27 JP JP2023049681A patent/JP2023078421A/ja active Pending
- 2023-11-17 US US18/512,473 patent/US20240124453A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GEP20237561B (en) | 2023-10-25 |
US20240124453A1 (en) | 2024-04-18 |
AU2020251841A1 (en) | 2021-10-07 |
MA55511A (fr) | 2022-02-09 |
ECSP21072994A (es) | 2021-11-18 |
CU20210080A7 (es) | 2022-05-11 |
CR20210501A (es) | 2021-11-02 |
CA3135555C (en) | 2023-09-19 |
CN113874363A (zh) | 2021-12-31 |
EP3947367A1 (en) | 2022-02-09 |
DOP2021000206A (es) | 2021-11-21 |
US11884664B2 (en) | 2024-01-30 |
JP2022527796A (ja) | 2022-06-06 |
JP7284830B2 (ja) | 2023-05-31 |
ZA202108443B (en) | 2023-04-26 |
PE20220141A1 (es) | 2022-01-27 |
TW202102490A (zh) | 2021-01-16 |
TWI766261B (zh) | 2022-06-01 |
US11634417B2 (en) | 2023-04-25 |
WO2020201991A1 (en) | 2020-10-08 |
IL286462A (en) | 2021-10-31 |
CL2021002542A1 (es) | 2022-06-24 |
KR20210146389A (ko) | 2021-12-03 |
US20200317665A1 (en) | 2020-10-08 |
US20220251083A1 (en) | 2022-08-11 |
BR112021018664A2 (pt) | 2021-11-23 |
UY38628A (es) | 2020-10-30 |
CA3135555A1 (en) | 2020-10-08 |
MX2021012122A (es) | 2021-11-03 |
JP2023078421A (ja) | 2023-06-06 |
SG11202110502PA (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21072994A (es) | Inhibidores de la proteína tirosina fosfatasa | |
NI202100027A (es) | Inhibidores de la proteína tirosina fosfatasa | |
CO7081155A2 (es) | Inhibidores de serina/treonina cinasa | |
DOP2022000117A (es) | Inhibidores de kras g12c | |
PE20200335A1 (es) | Compuestos que inhiben la proteina mcl-1 | |
AR116604A1 (es) | Inhibidores de kras g12c | |
BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
EA201101497A1 (ru) | Имидазопираны для применения в качестве ингибиторов киназ | |
MX2021015935A (es) | Formas de sal de acido bempedoico y metodos para utilizar el mismo. | |
ECSP10010507A (es) | Pirazolo (3, 4-b) piridina inhibidores de raf | |
ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
EA202090052A1 (ru) | Содержащие имидазол ингибиторы alk2 киназы | |
CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
CO2021010611A2 (es) | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x | |
SV2006002669A (es) | Inhibidores de quinasa c-fms ref. prd2368 | |
EA201991128A1 (ru) | ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ | |
EA202190801A1 (ru) | Ингибиторы протеинтирозинфосфатазы | |
EA201991141A1 (ru) | Усилители bmp | |
UY38946A (es) | Pirrolopiridinas como inhibidores de cinasa |